09:06 AM EDT, 09/03/2025 (MT Newswires) -- Aspire Biopharma ( ASBP ) said Wednesday that it has achieved positive final results from its randomized trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of its investigational new sublingual aspirin product versus chewed uncoated aspirin tablets in healthy adults for treatment of suspected acute myocardial infarction, heart attack.

The company said that the trial demonstrated that its sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid, compared with chewed aspirin tablets.

It added that the product was also safe and well-tolerated by patients, and no adverse events were reported.

Aspire Biopharma ( ASBP ) shares were down close to 9% in recent premarket activity.